Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes.
Oliveras A, de la Sierra A.
J Hum Hypertens. 2014 Apr;28(4):213-7. doi: 10.1038/jhh.2013.77. Epub 2013 Aug 29.
The renin-angiotensin-aldosterone system in primary and secondary hypertension.
del Greco F, Huang CM, Quintanilla A, Krumlovsky F, Roxe DM, Santhanam S.
Ann Clin Lab Sci. 1981 Nov-Dec;11(6):497-505.
Tumoral pulmonary hypertension.
Price LC, Seckl MJ, Dorfmüller P, Wort SJ.
Eur Respir Rev. 2019 Feb 6;28(151):180065. doi: 10.1183/16000617.0065-2018. Print 2019 Mar 31.
Preface.
Makowski GS.
Adv Clin Chem. 2017;82:ix. doi: 10.1016/S0065-2423(17)30056-2.
Parathyroid tumors.
Granberg PO, Cedermark B, Farnebo LO, Hamberger B, Werner S.
Curr Probl Cancer. 1985 Nov;9(11):1-52. doi: 10.1016/s0147-0272(85)80035-0.
[When should secondary hypertension be suspected?].
Koivuviita N.
Duodecim. 2009;125(10):1077-83.
Medical Measures in Hypertensives Considered Resistant.
Fadl Elmula FEM, Mariampillai JE, Heimark S, Kjeldsen SE, Burnier M.
Am J Hypertens. 2024 Apr 15;37(5):307-317. doi: 10.1093/ajh/hpad118.
[An unusual cause of hypertension].
El Aoud S, Tounsi H, Ben Ammou B, Chelbi E, Chaabène I, Ben Ahmed I, Amri R, Garbouj W, Bouzaidi K.
Ann Cardiol Angeiol (Paris). 2019 Feb;68(1):56-60. doi: 10.1016/j.ancard.2018.08.022. Epub 2018 Oct 2.
Evaluation of the elderly hypertensive.
Black HR.
Geriatrics. 1989 Oct;44 Suppl B:15-9.
Hypertension and hyperglycaemia are positively correlated with local invasion of early cervical cancer.
Shen T, Zhao J, Li W, Wang X, Gao Y, Wang Z, Hu S, Cai J.
Front Endocrinol (Lausanne). 2023 Dec 12;14:1280060. doi: 10.3389/fendo.2023.1280060. eCollection 2023.
